It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
COVID-19 has highlighted the need for remote cognitive testing, but the reliability and validity of virtual cognitive testing in Parkinson disease (PD) is unknown. Therefore, we assessed PD participants enrolled in an observational, cognition-focused study with an extensive cognitive battery completed both in-person and via video conference close in time. Data for 35 PD participants with normal cognition to mild dementia were analyzed. Only one test (semantic verbal fluency) demonstrated a difference in score by administration type, with a significantly better score virtually. Only three tests demonstrated good reliability for in-person versus virtual testing, but reliability values for visit 1 versus visit 2 were similarly low overall. Trail Making Test B was successfully administered virtually to only 18 participants due to technical issues. Virtual and in-person cognitive testing generate similar scores at the group level, but with poor to moderate reliability for most tests. Mode of test administration, learning effects, and technical difficulties explained little of the low test–retest reliability, indicating possible significant short-term variability in cognitive performance in PD in general, which has implications for clinical care and research. In-person cognitive testing with a neuropsychologist remains the gold standard, and it remains to be determined if virtual cognitive testing is feasible in PD.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Perelman School of Medicine at the University of Pennsylvania, Department of Neurology, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)
2 Perelman School of Medicine at the University of Pennsylvania, Department of Psychiatry, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)
3 Perelman School of Medicine at the University of Pennsylvania, Department of Biostatistics, Epidemiology and Informatics, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)
4 Perelman School of Medicine at the University of Pennsylvania, Department of Neurology, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); Perelman School of Medicine at the University of Pennsylvania, Department of Psychiatry, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); Philadelphia Veteran’s Affairs Medical Center, Parkinson’s Disease Research, Education and Clinical Center (PADRECC), Philadelphia, USA (GRID:grid.410355.6) (ISNI:0000 0004 0420 350X)